Skip to main content

IMS Events Main banner

MRD and Biomarkers

MRD and Biomarkers

Type here to filter the list

P-161: Gut microbiota differences among transplant ineligible patients with newly-diagnosed multiple myeloma treated with dara-len-dex
P-162: Cell-free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma
P-163: Study of cellular senescence in the bone marrow of Multiple Myeloma patients during disease progression
P-164: Establishing MRD Benchmark for Deployment of T-cell Redirection as Post Induction Therapy in Newly Diagnosed Multiple Myeloma
P-165: Advanced circulating tumor DNA (ctDNA)Profiling: Enhancing Non-Invasive Detection and Characterization of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)
P-166: Characteristics of immune-genes rearrangements in Chinese Multiple Myeloma patients
P-167: Urine Bence Jones proteins as a novel source for De Novo light chain sequencing
P-168: Serum BLYS and soluble (sBCMA) levels in Multiple Myeloma (MM) patients
P-169: Tumor Associated Macrophages’ cytokines; CD163, CCL4 and CCL2, as possible new biomarkers for Overall Survival and Transformation in Smoldering Multiple Myeloma.
P-170: Perspectives of single-center community hematologists/oncologists on minimal residual disease testing among patients with multiple myeloma
P-171: DARATUMUMAB AS CONSOLIDATION THERAPY IN MULTIPLE MYELOMA PATIENTS IN >VGPR/MRD POSITIVE AFTER FIRST LINE THERAPY: FINAL ANALYSIS OF THE MULTICENTRIC PHASE 2 STUDY DART4MM
P-172: Evaluating ethnicity-specific risk stratification models of multiple myeloma with global risk stratification models in real life scenario
P-173: Novel drug induction followed with autologous hematopoietic stem cell transplantation plus maintenance therapy improves survival of myeloma patients harboring 1p32 and overcomes its adverse prognosis
P-175: Real-world minimal residual disease testing patterns: findings from the Connect® MM Registry
P-176: Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma
P-177: PDCD6 Expression as a Prognostic Indicator in Multiple Myeloma
P-178: Leveraging AI for Modeling MRD and Survival Outcomes in Multiple Myeloma Based on Comprehensive and Up-to-Date Clinical Evidence
P-179: Rates of successful diagnostic clonal identification (ID) with Adaptive clonoSEQ®
P-180: MRD tracking in blood using a de novo sequencing from SPEP gel of M-protein in Multiple Myeloma Patients
P-182: IMPACT OF MINIMAL RESIDUAL DISEASE IN APHERESIS PRODUCT (aMRD) ASSESSED BY MULTIPARAMETRIC FLOW CYTOMETRY (MFC) IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS
P-183: Monoclonal Gammopathy of Uncertain Significance (MGUS) like Profile in Transplant-eligible Multiple Myeloma (MM) Patients: Clinic-Biological Characteristics and Prognosis Significance
P-184: The utility of mass spectrometry in defining minimal residual disease in treated multiple myeloma patients
P-186: Identifying a New Risk-Stratification Strategy by Including Single-Cell Biomarkers in Multiple Myeloma
P-187: Prognostic implication of JAM-A expressing circulating tumor plasma cells in multiple myeloma
P-188: Quantitation of immunoglobulin free light chains is impacted by glycosylated monoclonal proteins
P-191: The metabolic profile and prognostic model of multiple myeloma